Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xencor, an antibody discovery and development company, has entered into a technology licensing and evaluation agreement with Pfizer to optimize the performance of therapeutic monoclonal antibodies.
Subscribe to our email newsletter
Pfizer will apply Xencor’s Xtend antibody half-life prolongation technology and XmAb antibody-dependent cell-mediated cytotoxicity enhancing technology to its antibody drug candidates.
Under the terms of the agreement, Pfizer will have access to Xencor’s antibody optimization technology during a non-exclusive research period for evaluation of the technology in several of its discovery projects. In addition, Pfizer has taken a commercial license to Xencor’s technology for one program.
Xencor will receive an upfront payment from Pfizer and is eligible to receive additional consideration based on Pfizer’s successful commercialization of products that incorporate the Xencor technology. Further details of the agreement were not disclosed.
Bassil Dahiyat, CEO of Xencor, said: “We are delighted that a world class leader in the antibody space such as Pfizer will be broadly investigating the use of Xencor’s antibody optimization technology within its R&D organization to potentially enhance specific properties of its therapeutic antibody drug candidates.”